4.60

1.77% 0.08

After Hours: 4.51 -0.09 -1.96%

Alto Neuroscience Inc (ANRO)

Overview News Price History Discussions Forecast

Alto Neuroscience Inc stock is traded at $4.60, with a volume of 323.77K. It is up +1.77% in the last 24 hours and down -68.12% over the past month. Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Previous Close:

$4.52

Open:

$4.55

24h Volume:

323.77K

Relative Volume:

0.45

Market Cap:

$124.69M

Revenue:

Net Income/Loss:

$-49.81M

P/E Ratio:

EPS:

Net Cash Flow:

$-42.93M

1W Performance:

-4.96%

1M Performance:

-68.12%

6M Performance:

-63.11%

1Y Performance:

+0.00%

1-Day Range:

$4.41

$4.75

1-Week Range:

$4.36

$4.90

52-Week Range:

$3.61

$24.00

Alto Neuroscience Inc Stock (ANRO) Company Profile

Name

Alto Neuroscience Inc

Sector

Healthcare (1196)

Industry

Biotechnology (683)

Phone

773-255-5012

Address

650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ANRO's Discussions on Twitter

Compare ANRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANRO	4.60	124.69M	0	-49.81M	-42.93M	0.00
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Alto Neuroscience Inc Stock (ANRO) Latest News

Nov 18, 2024

FY2024 EPS Estimate for Alto Neuroscience Boosted by Analyst - MarketBeat

Nov 18, 2024

Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Nov 18, 2024

Nov 15, 2024

Wedbush Equities Analysts Reduce Earnings Estimates for ANRO - MarketBeat

Nov 15, 2024

RA Capital Management Reduces Stake in Alto Neuroscience Inc - GuruFocus.com

Nov 15, 2024

Nov 13, 2024

Stifel Nicolaus Has Lowered Expectations for Alto Neuroscience (NYSE:ANRO) Stock Price - MarketBeat

Nov 13, 2024

FMR LLC Acquires Shares in Alto Neuroscience Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance

Nov 12, 2024

Nov 11, 2024

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - PR Newswire

Nov 03, 2024

Nov 02, 2024

ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus.com

Nov 02, 2024

Nov 01, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out - AccessWire

Nov 01, 2024

Oct 31, 2024

Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect - AccessWire

Oct 31, 2024

Oct 30, 2024

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Oct 30, 2024

Oct 29, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Learn More About the Investigation - AccessWire

Oct 29, 2024

Oct 28, 2024